Cancer News and Research

Latest Cancer News and Research

ART to report on its molecular imaging products research at the World Molecular Imaging Congress

ART Advanced Research Technologies Inc. ("ART") (TSX:ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, announced today that current research relating to its molecular imaging products will be presented at poster sessions at the World Molecular Imaging Congress (WMIC), being held at the Palais des congres in Montreal, Canada, from September 23 to 26, 2009.

22 Sep 2009

Importance of residual thymopoiesis in aged adults

Doctor Manuel Leal is managing the Experimental Immune Virology Laboratory (in Virgen del Rocío University Hospital and Instituto de Biomedicina de Sevilla (IBIS), where clinic and basic science researchers work) where he leads a project to establish the functional nature of the thymus gland in adults. So far, it has been proven that this gland keeps on producing lymphocytes in the old age (Ferrando-Martínez et al. AGE, in press), which is a novelty because until very recently it was considered that this organ lost its immune capacity after the puberty.

22 Sep 2009

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the PressureWire™ Aeris technology, an interventional tool which measures Fractional Flow Reserve (FFR) to evaluate the severity of blood flow blockages in the arteries. This first-to-market technology helps interventional cardiologists better determine the ideal treatment option for their patients during coronary interventions, such as stent procedures.

22 Sep 2009

WHO emphasizes the importance of radon testing to prevent lung cancer

In simultaneous releases published around across the globe today, the World Health Organization (WHO) called for stronger action against indoor radon, the leading cause of lung cancer among U.S. and Canadian non-smokers.

22 Sep 2009

Patients with higher levels of vitamin D are less likely to die from skin cancer

New research shows higher levels of vitamin D may help improve survival for both bowel and skin cancer patients.

22 Sep 2009

Gene variant shows a strong gender bias for cancer predisposition

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

22 Sep 2009

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors.

22 Sep 2009

Older adults with vitamin D deficiency at a greater risk of heart disease and death

A new study by researchers at the University of Colorado Denver and Massachusetts General Hospital (MGH) shows vitamin D plays a vital role in reducing the risk of death associated with older age. The research, just published in the Journal of the American Geriatrics Society, evaluated the association between vitamin D levels in the blood and the death rates of those 65 and older. The study found that older adults with insufficient levels of vitamin D die from heart disease at greater rates that those with adequate levels of the vitamin.

22 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

NASDAQ issues noncompliance letter to Bionovo

Bionovo, Inc. (Nasdaq: BNVI) today announced that on September 15, 2009, the company received a letter from NASDAQ stating that, for the last 30 consecutive business days, the bid price of its common stock has closed below the minimum $1.00 per share requirement for continued listing on the NASDAQ Capital Market.

22 Sep 2009

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

New data on signalling proteins, called G proteins, may prove important in fighting diseases such as cardiovascular, neurodegenerative disorders, and cancer. For many decades scientists have puzzled on "How signalling proteins transport and organize in specific areas of the cell?" Researchers from Nano-Science Center and Department of Neuroscience and Pharmacology at the University of Copenhagen provide yet unrecognized clues to solve this mystery.

21 Sep 2009

Junk DNA could accelerate development of gene therapies

Scientists have identified how a protein enables sections of so-called junk DNA to be cut and pasted within genetic code - a finding which could speed development of gene therapies.

21 Sep 2009

GOP lawmakers opposed to reform reflect on their own experiences

Two Republican lawmakers with extensive personal interactions with the health care system warn of the dangers in health overhaul.

21 Sep 2009

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed the treatment portion, including all protocol-allowed retreatments of all patients, of its Phase 2 clinical trial of PV-10 for metastatic melanoma. The study involved treatment of 80 subjects with Stage III or Stage IV metastatic melanoma.

21 Sep 2009

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Anavex Life Sciences Corp., ("ANAVEX") (OTCBB: AVXL) today announced the completion of scale-up manufacturing of ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease.

21 Sep 2009

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Corning Incorporated (NYSE: GLW) and Geron Corporation (Nasdaq: GERN) today announced the successful development of novel synthetic surface matrices demonstrated to enhance and support the scalable manufacturing and growth of human embryonic stem cells (hESCs).

21 Sep 2009

Chronic viruses found living in prostate tumors

According to Dr. Ila R. Singh, an associate professor of pathology at the University of Utah, "for the first time we have analyzed prostate cancer and normal prostate tissue and found cancers are much more likely to have [the XMRV virus] ... It was also more likely to be present in more aggressive tumors," Singh said. "We found it in 20 percent of the least aggressive tumors and over 45 percent of the most aggressive tumors."

21 Sep 2009

The “Pink Star” fundraising campaign raises $1M for the National Breast Cancer Foundation

CKE Restaurants, Inc. today announced it has reached its goal of raising $1 million for breast cancer programs and awareness through its “Pink Star” fundraising campaign. During the three-week, in-store fundraiser that began in April, guests at Carl’s Jr.® and Hardee’s® restaurants across the United States donated to the campaign in support of the National Breast Cancer Foundation (NBCF).

21 Sep 2009

QualityMetric announces new tool to measure pain accurately

According to the National Centers for Health Statistics, 76.2 million Americans report problems with chronic pain; more than diabetes, heart disease, and cancer combined. The same report notes that the annual cost of chronic pain in the United States, including healthcare expenses, lost income, and productivity, is estimated to be $100 billion.

21 Sep 2009

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer (“HEAT study”) and has recommended that Celsion continue to enroll patients in the trial.

21 Sep 2009

Cancer News and Research

Latest Cancer News and Research

ART to report on its molecular imaging products research at the World Molecular Imaging Congress

Importance of residual thymopoiesis in aged adults

New wireless Fractional Flow Reserve system to evaluate blood flow blockages in the arteries

WHO emphasizes the importance of radon testing to prevent lung cancer

Patients with higher levels of vitamin D are less likely to die from skin cancer

Gene variant shows a strong gender bias for cancer predisposition

Interim data from Micromet's T-cell engaging BiTE antibody study for treating solid tumors

Older adults with vitamin D deficiency at a greater risk of heart disease and death

Novel cleavage sites for enzyme caspase-3 identified

NASDAQ issues noncompliance letter to Bionovo

G proteins could help fight cardiovascular, neurodegenerative disorders, and cancer

Junk DNA could accelerate development of gene therapies

GOP lawmakers opposed to reform reflect on their own experiences

Provectus' Phase 2 clinical trial of PV-10 for metastatic melanoma complete

Anavex completes manufacturing of Alzheimer's disease drug ANAVEX 2-73 for its clinical trials

Geron and Corning develop synthetic surface that supports the growth and differentiation of hESCs

Chronic viruses found living in prostate tumors

The “Pink Star” fundraising campaign raises $1M for the National Breast Cancer Foundation

QualityMetric announces new tool to measure pain accurately

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Cancer News and Research

Latest Cancer News and Research

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Newsletters you may be interested in